osteoporosis
Conditions
Interventions
Alfacalcidol (1mcg)+Ca(400mg) /day, 3 years
Alfacalcidol (1mcg)+Ca(400mg) +Raloxifene hydrochloride (60mg) /day, 3 years
Sponsors
Tokyo Women's Medical University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Patients corresponding to all three items below; 1. Patients that meets the primary osteoporosis diagnostic criteria 2. New outpatient 3. Patients who obtained the consent in writing from the patient or the family
Exclusion criteria
Exclusion criteria: 1. Secondary osteoporosis patients 2. Patients who has already been osteoporotic treatment 3. Patients whose serum calcium level is 10.5g/dl (albumin correction value) or more 4. Additional, patients who deemed inappropriate by physician as the object of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate trabecular bone structure using MDCT before and after 6 month, 1, 2 and 3 years treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate bone mineral density using dual-energy x-ray absorptiometry, the evidence of vertebral fracture using X-ray, and bone metabolic markers before and after 6 month, 1, 2 and 3 years treatment. | — |
Countries
Japan
Contacts
Public ContactChiharu Ishii
Tokyo Women's Medical University Department of Orthopedic Surgery
Outcome results
None listed